Showing 301 - 320 results of 3,907 for search 'Owlpen~', query time: 3.27s Refine Results
  1. 301
  2. 302
  3. 303
  4. 304
  5. 305
  6. 306
  7. 307
  8. 308
  9. 309
  10. 310
  11. 311

    Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial by Su H, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, Feng F

    Published 2025-02-01
    “…This study is designed to further validate the efficacy and safety of the combination therapy of low-dose lenvatinib and PD-1 inhibitor toripalimab in patients with recurrent PROC.Study Design and Methods: The study is designed as a multicenter, open-label, single-arm, prospective phase II study. …”
    Get full text
    Article
  12. 312
  13. 313
  14. 314
  15. 315
  16. 316
  17. 317
  18. 318
  19. 319

    Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial by Gang Chen, Dong-Chen Sun, Yi Ba, Ya-Xiong Zhang, Ting Zhou, Yuan-Yuan Zhao, Hong-Yun Zhao, Wen-Feng Fang, Yan Huang, Zhen Wang, Chao Deng, De-Sheng Hu, Wei Wang, Jin-Guan Lin, Gui-Ling Li, Su-Xia Luo, Zhi-Chao Fu, Hai-Sheng Zhu, Hui-Li Wang, Sheng-Li Cai, Xiao-Qiang Kang, Li Zhang, Yun-Peng Yang

    Published 2025-02-01
    “…Abstract Purpose Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carcinoma (NPC) and other solid tumors. …”
    Get full text
    Article
  20. 320